Think Surgical has earned a new U.S. Food and Drug Administration (FDA) 510(k) clearance for its TMINI miniature robotic system. The FDA nod covers use with Waldemar Link’s (LINK) LinkSymphoKnee (LSK) under a collaboration between the duo.

The Link SymphoKnee was added to Think Surgical’s ID-HUB, a proprietary databank of implant modules for use on the open platform version of TMINI in the U.S.

“At LINK, we have always prioritized innovation in orthopedic solutions, focusing on how we can empower our customers—the surgeons—with tools that can be used to elevate precision, adaptability, and patient outcomes,” said Peter Willenborg, CEO of LINK.

In September the TMINI robot was awarded FDA clearance for use with Zimmer Biomet’s Persona knee system. This made Think Surgical the only company at present with with a robotic system that has both an implant-exclusive option with the Persona knee and an open platform for implants from multiple other manufacturers for total knee replacement.

“THINK Surgical is excited to add the LinkSymphoKnee to the TMINI System. The open platform version of TMINI is now available with eight different knee designs from eight separate orthopedic companies offering surgeons the choice of single-radius, anatomic, and guided motion knees on a single robotic platform.” said Stuart Simpson, president and CEO of Think Surgical.

In July, the company also earned FDA clearance for its TMINI 1.1 system software, which allows positional refinement and optimization of the implant tailored to patient needs.